1CM Past Earnings Performance
Past criteria checks 0/6
1CM has been growing earnings at an average annual rate of 40.7%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 91.6% per year.
Key information
40.7%
Earnings growth rate
44.7%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 91.6% |
Return on equity | -6.4% |
Net Margin | -4.2% |
Last Earnings Update | 30 Nov 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How 1CM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Nov 23 | 40 | -2 | 7 | 0 |
31 Aug 23 | 35 | -1 | 6 | 0 |
31 May 23 | 24 | -2 | 7 | 0 |
28 Feb 23 | 15 | -3 | 6 | 0 |
30 Nov 22 | 8 | -3 | 4 | 0 |
31 Aug 22 | 1 | -5 | 3 | 0 |
31 May 22 | 1 | -5 | 4 | 0 |
28 Feb 22 | 1 | -5 | 5 | 0 |
30 Nov 21 | 1 | -5 | 4 | 0 |
31 Aug 21 | 0 | -5 | 4 | 0 |
31 May 21 | 0 | -4 | 2 | 0 |
28 Feb 21 | 0 | -3 | 1 | 0 |
30 Nov 20 | 0 | -3 | 1 | 0 |
31 Aug 20 | 0 | -3 | 1 | 0 |
31 May 20 | 0 | -28 | 1 | 0 |
29 Feb 20 | 0 | -28 | 1 | 0 |
30 Nov 19 | 0 | -28 | 1 | 0 |
31 Aug 19 | 0 | -29 | 1 | 0 |
31 May 19 | 0 | -7 | 5 | 0 |
28 Feb 19 | 0 | -8 | 6 | 0 |
30 Nov 18 | 0 | -7 | 6 | 0 |
31 Aug 18 | 0 | -6 | 6 | 0 |
31 May 18 | 0 | -2 | 2 | 0 |
28 Feb 18 | 0 | 0 | 0 | 0 |
30 Nov 17 | 0 | 0 | 0 | 0 |
31 Aug 17 | 0 | 0 | 0 | 0 |
31 May 17 | 0 | 0 | 0 | 0 |
28 Feb 17 | 0 | 0 | 0 | 0 |
30 Nov 16 | 0 | 0 | 0 | 0 |
31 Aug 16 | 0 | 0 | 0 | 0 |
31 May 16 | 0 | -1 | 0 | 0 |
29 Feb 16 | 0 | -1 | 0 | 0 |
30 Nov 15 | 0 | -1 | 0 | 0 |
31 Aug 15 | 0 | -1 | 0 | 0 |
31 May 15 | 0 | -1 | 0 | 0 |
28 Feb 15 | 0 | 0 | 0 | 0 |
30 Nov 14 | 0 | -2 | 0 | 0 |
31 Aug 14 | 0 | -2 | 0 | 0 |
Quality Earnings: EPIC is currently unprofitable.
Growing Profit Margin: EPIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPIC is unprofitable, but has reduced losses over the past 5 years at a rate of 40.7% per year.
Accelerating Growth: Unable to compare EPIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: EPIC has a negative Return on Equity (-6.36%), as it is currently unprofitable.